Zidovudine Prices June 2023
Product
|
Category |
Region |
Price |
Zidovudine |
Chemical |
USA |
562535 USD/MT (Jun, 23) |
Zidovudine |
Chemical |
China |
503644 USD/MT (Jun, 23) |
Zidovudine |
Chemical |
Germany |
580500 USD/MT (Jun, 23) |
The price of zidovudine in the United States for Q2 2023 reached 562535 USD/MT in June. Whereas, the price of zidovudine in China for Q2 2023 reached 503644 USD/MT in June. Similarly, the price of zidovudine in Germany for Q2 2023 reached 580500 USD/MT in June.
Zidovudine Price Trend, Market Analysis, and News
IMARC’s newly published report, titled “Zidovudine Pricing Report 2024: Price Trend, Chart, Market Analysis, News, Demand, Historical and Forecast Data,” offers an in-depth analysis of zidovudine pricing, covering an analysis of global and regional market trends and the critical factors driving these price movements.
It encompasses an in-depth review of spot price of zidovudine at major ports, a breakdown of prices including Ex Works, FOB, and CIF, alongside a region-wise dissection of zidovudine price trend across North America, Europe, Asia Pacific, Latin America, the Middle East and Africa.
The report examines the elements influencing zidovudine price fluctuations, such as changes in raw material costs, supply-demand dynamics, geopolitical factors, and industry-specific developments. Additionally, it integrates the latest market news, providing stakeholders with up-to-date information on market shifts, regulatory changes, and technological advancements, thereby offering a comprehensive overview that aids in strategic decision-making and forecasting.
Zidovudine Market Analysis
The global zidovudine market size reached US$ 1.1 Billion in 2023. By 2032, IMARC Group expects the market to reach US$ 1.68 Billion, at a projected CAGR of 4.80% during 2023-2032.
- An important development in the zidovudine industry is the drug's growing uptake in low- and middle-income nations (LMICs). The World Health Organization (WHO) states that zidovudine is still an essential part of HIV therapy regimens, especially in regions with limited resources. The use of zidovudine in first- and second-line therapy choices is highlighted in the WHO's 2023 HIV treatment guidelines, particularly in cases where medication resistance has developed. Its established effectiveness and lower cost in comparison to more recent antiretroviral medications are the main reasons for its broad use. Zidovudine is now widely available in these areas’ thanks in large part to the Global Fund and PEPFAR (President's Emergency Plan for AIDS Relief), which have provided finance and assistance for the acquisition and distribution of the medication. Thus, zidovudine's demand in low- and middle-income countries (LMICs) keeps rising, indicating the drug's vital role in international efforts to treat HIV.
- There is a tendency in the zidovudine market toward the usage of combination therapies increasing. Zidovudine should be used in conjunction with other antiretrovirals, according to U.S. Department of Health and Human Services (HHS) guidelines, to improve treatment efficacy and lower the risk of drug resistance. Zidovudine-containing fixed-dose combos (FDCs), including Combivir (zidovudine plus lamivudine), are becoming increasingly widely used. Clinical research demonstrating that combination medicines enhance patient adherence and outcomes over monotherapy lends credence to this trend. The National Institutes of Health (NIH) has released new data that indicates combination medicines, such as zidovudine, have significantly reduced patients' HIV viral loads, improving their quality of life and lowering transmission rates.
- Another noteworthy development in the zidovudine market is the focus on cost-cutting and generic manufacture. As a result of patent expirations, a few generic producers have entered the market, bringing zidovudine's price down and increasing its accessibility to a wider range of people. U.S. Food and Drug Administration (FDA) has approved numerous generic zidovudine variants, ensuring a competitive market that benefits customers. The expansion of treatment coverage, particularly in marginalized regions, has been facilitated by the availability of reasonably priced generic zidovudine, according to data from the Centers for Disease Control and Prevention (CDC). In the context of global health campaigns, this trend is especially important because groups like UNAIDS and Médecins Sans Frontières (MSF) advocate for reduced drug costs to provide HIV treatment for all people. The emphasis on generic manufacture promotes ongoing innovation in the antiretroviral market in addition to providing cost-effective treatment.
Zidovudine News
The report covers the latest developments, updates, and trends impacting the global zidovudine market, providing stakeholders with timely and relevant information. This segment covers a wide array of news items, including the inauguration of new production facilities, advancements in zidovudine production technologies, strategic market expansions by key industry players, and significant mergers and acquisitions that impact the zidovudine price trend.
Latest developments in the zidovudine industry:
- In 2024, Cipla partnered with CSIR-CDRI to advance ophthalmic antifungal treatments and formed a joint venture with Kemwell Biopharma and Manipal Education & Medical Group for cell therapy products. These collaborations aim to innovate and expand Cipla’s zidovudine market reach in critical therapeutic areas.
- In 2023, Cognizant announced an expansion of its relationship with Gilead Sciences. Gilead is a leading biopharmaceutical company advancing innovative medicines to prevent and treat life-threatening diseases. Gilead Sciences is focusing on technological advancements and strategic partnerships to enhance its zidovudine offerings. The company is leveraging AI and big data analytics to optimize its drug development and manufacturing processes.
Product Description
Zidovudine, commonly referred to as azidothymidine, or AZT, is a ground-breaking antiviral drug that is mostly used to treat and manage HIV/AIDS. Reverse transcriptase is an enzyme required for HIV replication, and as such, it functions as a nucleoside reverse transcriptase inhibitor (NRTI). Zidovudine efficiently stops the virus from multiplying and infecting healthy cells by integrating itself into the viral DNA.
As the first medication accessible for HIV treatment, zidovudine represented a historic milestone when it was originally approved by the FDA in 1987. To prevent HIV from being transferred from mother to child during childbirth, it is typically given orally as pills, capsules, or syrup. In more extreme circumstances, intravenous delivery of the medication may be necessary. To increase the effectiveness of highly active antiretroviral therapy (HAART), zidovudine is frequently used in combination with other antiretroviral medications.
Zidovudine has been mainly replaced by more recent antiretroviral drugs that have higher safety profiles and fewer side effects, but it is still an important choice, especially in situations where resources are scarce. Anemia, neutropenia, and gastrointestinal issues are typical adverse effects. Zidovudine continues to be used in some situations and has played a significant part in the history of HIV treatment, despite these difficulties, which highlights its continued significance in world health.
Regional Coverage
The report provides a detailed analysis of the zidovudine market across different regions, each with unique pricing dynamics influenced by localized market conditions, supply chain intricacies, and geopolitical factors. This includes price trends, price forecast and supply and demand trends for each region, along with spot prices by major ports. The report also provides coverage of ex-works, FOB, and CIF prices, as well as the key factors influencing the zidovudine price trend.
Global Zidovudine Price
The report offers a holistic view of the global zidovudine pricing trends in the form of zidovudine price charts, reflecting the worldwide interplay of supply-demand balances, international trade policies, and overarching economic factors that shape the market on a macro level. This comprehensive analysis not only highlights current price of zidovudine but also provides insights into historical price trends, enabling stakeholders to understand past fluctuations and their underlying causes.
The report also delves into price forecast models, projecting future price movements based on a variety of indicators such as expected changes in supply chain dynamics, anticipated policy shifts, and emerging market trends. By examining these factors, the report equips industry participants with the necessary tools to make informed strategic decisions, manage risks, and capitalize on market opportunities. Furthermore, it includes a detailed zidovudine demand analysis, breaking down regional variations and identifying key drivers specific to each geographic market, thus offering a nuanced understanding of the global pricing landscape.
Europe Zidovudine Price
European zidovudine prices are examined, highlighting the market-specific influences in the region, such as stringent environmental regulations, the competitive landscape, and import-export imbalances that significantly affect pricing structures.
This analysis can be extended to include detailed zidovudine price information for a comprehensive list of countries.
Region |
Countries Covered |
Europe |
Germany, France, United Kingdom, Italy, Spain, Russia, Turkey, Netherlands, Poland, Sweden, Belgium, Austria, Ireland, Switzerland, Norway, Denmark, Romania, Finland, Czech Republic, Portugal, and Greece, among other European countries. |
North America Zidovudine Price
The analysis of zidovudine prices in North America delves into the regional industry dynamics, encompassing the impact of local production capacities and the trade flows between North America and other significant global markets.
Specific zidovudine historical data within the United States and Canada can also be provided.
Region |
Countries Covered |
North America |
United States and Canada |
Middle East and Africa Zidovudine Price
The report explores the zidovudine pricing trends in the Middle East and Africa, considering factors like regional industrial growth, the availability of natural resources, and geopolitical tensions that uniquely influence market prices.
In addition to region-wise data, information on zidovudine prices for countries can also be provided.
Region |
Countries Covered |
Middle East & Africa |
Saudi Arabia, UAE, Israel, Iran, South Africa, Nigeria, Oman, Kuwait, Qatar, Iraq, Egypt, Algeria, and Morocco, among other Middle Eastern and African countries. |
Asia Pacific Zidovudine Price
The zidovudine pricing trends in Asia Pacific are examined, reflecting the role of the region as a major global production hub and consumer market, with price dynamics heavily influenced by supply chain efficiencies, regional demand surges, and policy shifts in major economies.
This zidovudine price analysis can be expanded to include a comprehensive list of countries within the region.
Region |
Countries Covered |
Asia Pacific |
China, India, Indonesia, Pakistan, Bangladesh, Japan, Philippines, Vietnam, Thailand, South Korea, Malaysia, Nepal, Taiwan, Sri Lanka, Hongkong, Singapore, Australia, and New Zealand, among other Asian countries. |
Latin America Zidovudine Price
The analysis of Zidovudine prices in Latin America provides a detailed overview, reflecting the unique market dynamics in the region influenced by economic policies, industrial growth, and trade frameworks.
This comprehensive review can be extended to include specific countries within the region.
Region |
Countries Covered |
Latin America |
Brazil, Mexico, Argentina, Columbia, Chile, Ecuador, and Peru, among other Latin American countries. |
Report Coverage
Key Attributes |
Details |
Product Name |
Zidovudine |
Report Features |
Exploration of Historical Trends and Market Outlook, Industry Demand, Industry Supply, Gap Analysis, Challenges, Zidovudine Price Analysis, and Segment-Wise Assessment. |
Currency/Units |
US$ (Data can also be provided in local currency) or Metric Tons |
Region/Countries Covered |
The current coverage includes analysis at the global and regional levels only.
Based on your requirements, we can also customize the report and provide specific information for the following countries:
Asia Pacific: China, India, Indonesia, Pakistan, Bangladesh, Japan, Philippines, Vietnam, Thailand, South Korea, Malaysia, Nepal, Taiwan, Sri Lanka, Hongkong, Singapore, Australia, and New Zealand*
Europe: Germany, France, United Kingdom, Italy, Spain, Russia, Turkey, Netherlands, Poland, Sweden, Belgium, Austria, Ireland, Switzerland, Norway, Denmark, Romania, Finland, Czech Republic, Portugal and Greece*
North America: United States and Canada
Latin America: Brazil, Mexico, Argentina, Columbia, Chile, Ecuador, and Peru*
Middle East & Africa: Saudi Arabia, UAE, Israel, Iran, South Africa, Nigeria, Oman, Kuwait, Qatar, Iraq, Egypt, Algeria, and Morocco*
*The list of countries presented is not exhaustive. Information on additional countries can be provided if required by the client. |
Information Covered for Key Suppliers |
- Company Overview
- Business Description
- Product Portfolio
- Recent Trends and Developments
|
Customization Scope |
The report can be customized as per the requirements of the customer |
Report Price and Purchase Option |
Plan A: Monthly Updates - Annual Subscription
- Scope
- Historical Data for the Current Month
- Forecast for Next Month
- Total Deliverables Per Year: 12 (One Per Month)
- Includes: One PDF and Excel datasheet per month, Post Purchase Analyst Support throughout the year
Plan B: Quarterly Updates - Annual Subscription
- Scope
- Historical Data for the Current Quarter
- Forecast for Next Quarter
- Total Deliverables Per Year: 4 (One Per Quarter)
- Includes: One PDF and Excel datasheet per Quarter, Post Purchase Analyst Support throughout the year
Plan C: Biannually Updates - Annual Subscription
- Scope
- Historical Data for the Current Half
- Forecast for the Next Half
- Total Deliverables Per Year: 2 (One Per 6 Months)
- Includes: One PDF and Excel datasheet per Half, Post Purchase Analyst Support throughout the year
|
Post-Sale Analyst Support |
360-degree analyst support after report delivery |
Delivery Format |
PDF and Excel through email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Benefits for Stakeholders:
- IMARC’s report presents a detailed analysis of zidovudine pricing, covering global and regional trends, spot prices at key ports, and a breakdown of Ex Works, FOB, and CIF prices.
- The study examines factors affecting zidovudine price trend, including raw material costs, supply-demand shifts, geopolitical impacts, and industry developments, offering insights for informed decision-making.
- The competitive landscape review equips stakeholders with crucial insights into the latest market news, regulatory changes, and technological advancements, ensuring a well-rounded, strategic overview for forecasting and planning.
- IMARC offers various subscription options, including monthly, quarterly, and biannual updates, allowing clients to stay informed with the latest market trends, ongoing developments, and comprehensive market insights. The zidovudine price charts ensure our clients remain at the forefront of the industry.